
June 23 (Reuters) - Revolution Medicines Inc RVMD.O:
REVOLUTION MEDICINES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DARAXONRASIB IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER WITH KRAS G12 MUTATIONS
REVOLUTION MEDICINES INC - DESIGNATION BASED ON DATA FROM PHASE 1 TRIAL
REVOLUTION MEDICINES INC - PHASE 3 STUDY OF DARAXONRASIB EXPECTED TO COMPLETE ENROLLMENT THIS YEAR